A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.
about
A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.Asymmetric synthesis of a CBI-based cyclic N-acyl O-amino phenol duocarmycin prodrug.Synthesis, characterization, and evaluation of pluronic-based β-cyclodextrin polyrotaxanes for mobilization of accumulated cholesterol from Niemann-Pick type C fibroblasts.A five-membered lactone prodrug of CBI-based analogs of the duocarmycinsEfficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.Design and synthesis of pyrazole/isoxazole linked arylcinnamides as tubulin polymerization inhibitors and potential antiproliferative agents.Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions.Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy.Antimalarial chemotherapy: artemisinin-derived dimer carbonates and thiocarbonates.The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.Gold-catalyzed oxycyclization of allenic carbamates: expeditious synthesis of 1,3-oxazin-2-ones.Copper-catalyzed intermolecular C(sp3)-H bond functionalization towards the synthesis of tertiary carbamates.Synthesis of densely functionalised 5-halogen-1,3-oxazin-2-ones by halogen-mediated regioselective cyclisation of N-Cbz-protected propargylic amines: a combined experimental and theoretical study.The Difference a Single Atom Can Make: Synthesis and Design at the Chemistry-Biology Interface.An overview of recent advances in duplex DNA recognition by small molecules.
P2860
Q30661435-38003043-E60E-43F5-9FE6-AF26F7262AB3Q34361165-89730301-C393-4CB5-84F3-838EB5112276Q34656648-2F28BCFF-FD9A-41C6-8029-D4AAD19F00E6Q35694557-C3FDC9F5-C70B-486C-B0AC-370318DB6528Q36943532-DFF7B78E-8437-4446-B674-F7A24CB77E61Q38841186-284F28D2-2164-4182-B23C-A587922E67B4Q38968855-AA7EA6B5-5AF6-4AAA-AC3E-C6259D857669Q39229406-641C108B-E581-4BBE-B3B2-6B306DCFF581Q41462510-776D7A2E-5697-4441-8B56-72B4E5CE0130Q42000397-11DCBEEE-554E-4213-8244-6108CEEBE45CQ42149442-ABE9703B-D864-4B2D-AEB3-1BFF5533DA11Q43884810-D250BA52-2330-47EB-A5AC-0FCD9536E223Q45911225-E706124A-185E-4700-81CE-80A06F739DC0Q46236467-E5E6F81C-E97D-45CD-A192-BCED61873B3AQ55476273-1C5556C2-D5B8-413A-A4E2-C2423021099A
P2860
A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A novel, unusually efficacious ...... eleases no residual byproduct.
@ast
A novel, unusually efficacious ...... eleases no residual byproduct.
@en
type
label
A novel, unusually efficacious ...... eleases no residual byproduct.
@ast
A novel, unusually efficacious ...... eleases no residual byproduct.
@en
prefLabel
A novel, unusually efficacious ...... eleases no residual byproduct.
@ast
A novel, unusually efficacious ...... eleases no residual byproduct.
@en
P2093
P2860
P356
P1476
A novel, unusually efficacious ...... eleases no residual byproduct.
@en
P2093
Amanda L Wolfe
Dale L Boger
George A Vielhauer
Katharine K Duncan
Nikhil K Parelkar
Scott J Weir
P2860
P304
P356
10.1021/JM300330B
P407
P577
2012-06-12T00:00:00Z